Summary

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

• Isatuximab-irfc (Sarclisa) is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Additionally, it is used in combination with carfilzomib and dexamethasone for treating adults with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
• The information was derived from six systematic reviews/meta-analyses focusing on Sarclisa (isatuximab-irfc).
• In terms of safety, isatuximab has been associated with higher rates of hematologic adverse events such as thrombocytopenia and neutropenia, along with non-hematologic adverse events like infections, dyspnea, diarrhea, pyrexia, and back pain compared to treatments excluding anti-CD38 monoclonal antibodies.
• Regarding effectiveness comparison against other drugs, isatuximab showed improvement in progression-free survival for multiple myeloma patients; it significantly improved PFS and overall survival when combined with immunomodulatory drugs or proteasome inhibitors; demonstrated a solid overall response rate against other triplet therapies based on pomalidomide and dexamethasone; and ranked high among novel agents used in relapsed or refractory multiple myeloma treatments according to network meta-analysis results.
• The drug shows promising results as monotherapy but even better outcomes when used in combination therapies, suggesting its pivotal effectiveness, especially useful for tackling resistant forms of multiple myeloma.
• Population types considered include those having high-risk genetic profiles like +1q abnormalities cases refractory to lenalidomide, making it an essential component of future multiple myeloma therapy paradigms due to its efficacy across a broad spectrum of populations.